Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point ...

Restoring sight after whole human eye transplant remains a long-term goal, and the optic nerve is the limiting factor, ...

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...

Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose ...

Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...

Innovation in therapeutics has a lot on the horizon, he said, but all of those drugs and innovations can only be delivered by ...

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye ...

In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.